Shares of Quidel (QDEL), also known as QuidelOrtho Corp, soared 8.70% in pre-market trading on Thursday, following a significant target price upgrade from UBS. The investment bank raised its price target for QuidelOrtho from $26 to $31, signaling increased confidence in the company's future performance.

The substantial boost in the target price appears to have sparked investor optimism, driving the stock's pre-market rally. UBS's move suggests that the bank sees potential for growth and improved financial performance in QuidelOrtho's business, which specializes in diagnostic healthcare products.

However, it's worth noting that analyst opinions on QuidelOrtho remain mixed. Recent reports indicate that market experts are divided in their assessments of the company's prospects. This divergence in analyst views adds an element of complexity to the stock's outlook, despite the positive pre-market movement. Investors will likely be watching closely to see if the stock can maintain its momentum when regular trading begins and how it performs in the coming days as the market digests these conflicting signals.